Despite an FDA advisory committee’s narrow ruling that Provention Bio Inc.’s teplizumab has benefits that outweigh the risks in treating diabetes, the agency sent the company a complete response ...
The FDA in a complete response letter to Replimune maintained its original objection to the single-arm trial the biotech used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results